SK286235B6 - Spôsob zisťovania transformačnej schopnosti látky, spôsob zisťovania predispozície buniek stať sa nádorovými bunkami, použitie nukleovej kyseliny a diagnostická súprava - Google Patents

Spôsob zisťovania transformačnej schopnosti látky, spôsob zisťovania predispozície buniek stať sa nádorovými bunkami, použitie nukleovej kyseliny a diagnostická súprava Download PDF

Info

Publication number
SK286235B6
SK286235B6 SK190-2000A SK1902000A SK286235B6 SK 286235 B6 SK286235 B6 SK 286235B6 SK 1902000 A SK1902000 A SK 1902000A SK 286235 B6 SK286235 B6 SK 286235B6
Authority
SK
Slovakia
Prior art keywords
apoptin
cells
cell
apoptosis
activity
Prior art date
Application number
SK190-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK1902000A3 (en
Inventor
Mathieu Hubertus Maria Noteborn
Original Assignee
Leadd B. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd B. V. filed Critical Leadd B. V.
Publication of SK1902000A3 publication Critical patent/SK1902000A3/sk
Publication of SK286235B6 publication Critical patent/SK286235B6/sk

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
SK190-2000A 1997-08-12 1998-08-11 Spôsob zisťovania transformačnej schopnosti látky, spôsob zisťovania predispozície buniek stať sa nádorovými bunkami, použitie nukleovej kyseliny a diagnostická súprava SK286235B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202501 1997-08-12
PCT/NL1998/000457 WO1999008108A1 (en) 1997-08-12 1998-08-11 Determining the transforming capability of agents

Publications (2)

Publication Number Publication Date
SK1902000A3 SK1902000A3 (en) 2000-11-07
SK286235B6 true SK286235B6 (sk) 2008-06-06

Family

ID=8228640

Family Applications (1)

Application Number Title Priority Date Filing Date
SK190-2000A SK286235B6 (sk) 1997-08-12 1998-08-11 Spôsob zisťovania transformačnej schopnosti látky, spôsob zisťovania predispozície buniek stať sa nádorovými bunkami, použitie nukleovej kyseliny a diagnostická súprava

Country Status (16)

Country Link
US (1) US6528247B1 (de)
EP (1) EP1004021B1 (de)
JP (1) JP4287588B2 (de)
KR (1) KR20010022812A (de)
AT (1) ATE283478T1 (de)
AU (1) AU756587B2 (de)
BR (1) BR9811163A (de)
CA (1) CA2301401C (de)
CZ (1) CZ299874B6 (de)
DE (1) DE69827805T2 (de)
NO (1) NO326659B1 (de)
NZ (1) NZ502800A (de)
PL (1) PL196605B1 (de)
RU (1) RU2214598C2 (de)
SK (1) SK286235B6 (de)
WO (1) WO1999008108A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW514581B (en) * 1999-09-02 2002-12-21 Ciba Sc Holding Ag A method of protecting wood against light-induced degradation by treatment with an impregnation which penetrates the surface of the wood
DK1083224T3 (da) 1999-09-02 2007-04-10 Leadd Bv Apoptin-associerende protein
CA2393859A1 (en) 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
EP1199363A1 (de) 2000-10-20 2002-04-24 Leadd B.V. Phosphorylationsmodifikationen von Apoptin
ATE414776T1 (de) * 2001-03-30 2008-12-15 Leadd Bv Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2003904086A0 (en) 2003-08-04 2003-08-21 Cochlear Limited Implant battery short circuit protection
RU2325200C2 (ru) * 2006-02-20 2008-05-27 Федеральное государственное унитарное предприятие "НПО Астрофизика" Способ лазерного подавления роста и элиминации злокачественных образований
RU2340349C2 (ru) * 2006-08-10 2008-12-10 Геннадий Петрович Македонов Способ стимулирования апоптоза
CA2822938A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
CA2860914A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
DK0569367T3 (da) * 1991-01-15 1998-10-07 Biotie Therapies Oy Detektering af syndecanindhold i biologiske materialer, såsom væv og kropsvæsker, som indikationer på maligne transformatio
EP0878546A1 (de) * 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
SK278857B6 (sk) * 1992-03-19 1998-04-08 Prírodovedecká Fakulta Uk Spôsob testovania cytotoxicity a genotoxicity chem
EP0830604B1 (de) * 1995-06-07 2003-05-28 Leadd B.V. Verwendungen von apoptin
JPH1015250A (ja) 1996-06-28 1998-01-20 Sega Enterp Ltd ゲーム装置
EP0921192A1 (de) * 1997-12-03 1999-06-09 Leadd B.V. Molekulen interagierend mit Apoptin
EP0927757A1 (de) * 1997-12-03 1999-07-07 Leadd B.V. Verfahren und Mitteln um Apoptose zu induzieren durch Interferenz mit Bip-ähnliche Proteine

Also Published As

Publication number Publication date
EP1004021B1 (de) 2004-11-24
SK1902000A3 (en) 2000-11-07
JP2001512829A (ja) 2001-08-28
KR20010022812A (ko) 2001-03-26
NO20000736D0 (no) 2000-02-14
NZ502800A (en) 2002-10-25
NO20000736L (no) 2000-04-11
NO326659B1 (no) 2009-01-26
PL196605B1 (pl) 2008-01-31
DE69827805T2 (de) 2005-12-15
WO1999008108A1 (en) 1999-02-18
JP4287588B2 (ja) 2009-07-01
CA2301401C (en) 2008-10-21
DE69827805D1 (de) 2004-12-30
AU756587B2 (en) 2003-01-16
EP1004021A1 (de) 2000-05-31
CZ2000479A3 (cs) 2000-06-14
CA2301401A1 (en) 1999-02-18
ATE283478T1 (de) 2004-12-15
BR9811163A (pt) 2000-07-25
PL338683A1 (en) 2000-11-20
CZ299874B6 (cs) 2008-12-17
US6528247B1 (en) 2003-03-04
RU2214598C2 (ru) 2003-10-20
AU8752998A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
Fang et al. Bcl-xL rescues WEHI 231 B lymphocytes from oxidant-mediated death following diverse apoptotic stimuli
Shinoura et al. Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy
Hayward et al. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1
Howes et al. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53.
Slack et al. Cells differentiating into neuroectoderm undergo apoptosis in the absence of functional retinoblastoma family proteins.
US7927816B2 (en) Methods for identifying modulators of apoptosis
Feddersen et al. In vivo viability of postmitotic Purkinje neurons requires pRb family member function
SK286235B6 (sk) Spôsob zisťovania transformačnej schopnosti látky, spôsob zisťovania predispozície buniek stať sa nádorovými bunkami, použitie nukleovej kyseliny a diagnostická súprava
Singh et al. The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation
WO1994022487A1 (en) Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
Gunji et al. TEL/AML1 shows dominant-negative effects over TEL as well as AML1
JP2001521387A (ja) アポトーシス誘発タンパク質ｖｐ２および／またはアポプチンを発現する遺伝子伝達体
MXPA00001410A (en) Determining the transforming capability of agents
Heinrich et al. ATF3 regulates the expression of AChE during stress
Regeling et al. Mice defective in p53 nuclear localization signal 1 exhibit exencephaly
Ohno et al. Dispensable role of protein 4.1 B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1
UA73271C2 (en) Genes delivery vector expressing proteins vp2 and/or apoptine, causing apoptose induction
Hayward et al. Rescue and isolation of Rb-deficient prostate epithelium by tissue recombination
Sun Characterization of Rb1 function in the absence of normal E2F binding
US20050042671A1 (en) Modulation of angiogenesis
US20050013803A1 (en) Diagnosing and treating cancer cells using mutant viruses
Wang et al. Adenovirus E1A Expression Controlled by the Red Pigment Promoter in Transgenic Mice: A Model for Developmental Abnormalities of the Eye’
Morgenbesser Differential function of Myc-family oncoproteins in proliferation and differentiation in a well-defined cell type, in vivo
Apara Regenerative failure of the optic nerve: The role of KLFs and phosphorylation
Liegeois Analysis of the mammalian G1 checkpoint

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20100811